Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial | Trials | JAMA Oncology | JAMA Network

Tang C, Sherry AD, Haymaker C, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9(6):825–834. doi:10.1001/jamaoncol.2023.0161 This article is featured in JAMA+. Impactful topics, curated by experts. Trial Protocol eAppendix. Expanded Flow Cytometry Methods eFigure 1. Flow Cytometry Gating Displaying Gating Strategy for T Cells eFigure 2. Progression-Free Survival in Castration-Sensitive Patients eFigure 3. Secondary Endpoints eFigure 4. Change in CD4+ and CD8+ T Cell Populations eFigure 5. Analysis of Ki-67 Expression in CD8+ and CD4+ T Cell Populations eFigure 6. Association of TCR Sequencing Metrics and Flow Cytometry Metrics eTable 1. T Cell Flow Cytometry Panel Design eTable 2. Stratification Factors eTable 3. Initial Progression Diagnosis eTable 4. Adverse Events eTable 5. LMM Analysis Assessing Association of Quality-of-Life Metrics With Treatment Vari

Tang C, Sherry AD, Haymaker C, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9(6):825–834. doi:10.1001/jamaoncol.2023.0161 This article is featured in JAMA+. Impactful topics, curated by experts. Trial Protocol eAppendix. Expanded Flow Cytometry Methods eFigure 1. Flow Cytometry Gating Displaying Gating Strategy for T Cells eFigure 2. Progression-Free Survival in Castration-Sensitive Patients eFigure 3. Secondary Endpoints eFigure 4. Change in CD4+ and CD8+ T Cel